Long COVID top news

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antifungal prophylaxis effective in HSCT patients

Publish date:: July 22, 2020

Key clinical point: Isavuconazole prophylaxis appeared effective against invasive fungal infection in patients undergoing HCST.

Major finding: The rate of breakthrough candidemia was 3.1%, and there were no invasive mold infections.

Study details: An open label single arm study of 95 hematopoietic stem cell patients.

Disclosures: The authors reported funding from a variety of pharmaceutical and biotechnology companies.

Citation:

Stern A et al. Biol Blood Marrow Transplant. 2020;26:1195-1202.

This Week's Must Reads

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Three genes could predict congenital Zika infection susceptibility,

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

Must Reads in Invasive fungal infections

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

Infection with Fusarium is a risk in hematology patients,

Primary immunodeficiency disease patients have high risk of invasive fungal disease,

MicroRNAs can distinguish invasive aspergillosis in lung transplant recipients,

Saliva-controlled sputum culture aids diagnosis of deep pulmonary infections,